Cancer drug Keytruda maker Merck buys Verona before patent cliff Merck’s blockbuster drug Keytruda to lose key patent protections in 2028 ...

On July 9, Merck announced that it would acquire Verona Pharma, a U.K.-based biotechnology company specializing in the development of medicines for respiratory diseases. Merck will pay $10 billion in ...

No improvement in clinical outcomes occurred among inpatients with COVID-19 who received nirtmatrelvir-ritonavir or molnupiravir in addition to usual care.

For $10 billion, Merck is acquiring a promising healthcare company which is in the early stages of its growth. Key to its ...

In relapsing-remitting multiple sclerosis, activation of the peripheral immune system can lead to focal inflammation within the CNS. Over the past three decades, therapeutic development has been ...

A recent Merck Sharp & Dohme LLC patent details new substituted isoquinoline derivatives acting as tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or PTPN2 (TCPTP) inhibitors ...

The Japanese government discarded Covid-19 oral medicines believed to be worth around 240 billion yen (US$1.6 billion) in the ...

The Japanese government discarded Covid-19 oral medicines believed to be worth around 240 billion yen (RM6.85 billion) in the ...

The government discarded COVID-19 oral medicines believed to be worth around 240 billion yen ($1.6 billion) in the fiscal ...

Merck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...

Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...

MRK's regulatory filing for once-daily HIV pill DOR/ISL gets FDA acceptance, with a decision expected by April 2026.